Search clinical trials for: Peginterferon alpha-2a Ribavirin

Total 770 results

Hoffmann-La Roche

Completed

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

France, Sweden, Austria, Hungary, Poland, Romania, Slovenia, Croatia, Serbia, Canada, Brazil, Morocco, Mexico, Macedonia, The Former Yugoslav Republic of
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Antiviral Treatment of Chronic Hepatitis B
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
PharmaEssentia

Completed

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Chronic Hepatitis C Virus Infection

Korea, Republic of, Taiwan, China
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Hepatitis C

Austria
National Institute of Allergy and Infectious Diseases...

Completed

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

HIV Infections | Hepatitis C | Liver Disease

United States, Puerto Rico
Yonsei University

Completed

A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon

Chronic Hepatitis B

Korea, Republic of
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers

Chronic Viral Hepatitis C

Brazil
Hoffmann-La Roche

Withdrawn

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Hepatitis C, Chronic
University of Hamburg-Eppendorf
Hoffmann-La Roche; Universitätsklinikum Hamburg-Eppendorf

Unknown

Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy

Hepatitis C, Chronic | Relapse

Germany
Beijing Ditan Hospital

Unknown

The Changes of Treg Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

Hepatitis B, Chronic

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Hepatitis C, Chronic

United States, Canada, Slovakia, Poland, New Zealand, France, Australia
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Breast Cancer | Metastatic Cancer

United States
Beijing Ditan Hospital

Unknown

The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
Bristol-Myers Squibb

Terminated

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Hepatitis C

United States
Weill Medical College of Cornell University
Vertex Pharmaceuticals Incorporated

Completed

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Hepatitis C
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Hepatitis C, Chronic

Russian Federation, Korea, Republic of
University of Chicago

Terminated

Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

Hepatitis C

United States
Kirby Institute

Completed

Treatment of Recently Acquired Hepatitis C Virus Infection (ATAHC-II)

Acute Hepatitis C

Australia
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Alios Biopharma Inc.

Withdrawn

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Hepatitis B, Chronic
Yao Xie

Unknown

The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Terminated

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Hepatitis C, Chronic

Taiwan, Korea, Republic of, Thailand
Beijing Ditan Hospital

Unknown

The Changes of Cytokines During Antiviral Therapy

Chronic Hepatitis B Infection

China
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Chronic Hepatitis C (CHC)

Japan
Bristol-Myers Squibb

Completed

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Hepatitis C

France, United Kingdom, Spain, United States, Italy, Puerto Rico, Greece
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
Hoffmann-La Roche

Completed

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

Bulgaria
University Hospital, Geneva

Completed

Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant

Hepatitis C
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

HIV Infections

United States
Hoffmann-La Roche

Completed

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Hungary
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA); YR Gaitonde Centre for AIDS Research...

Completed

Directly Observed Therapy for HCV in Chennai, India (C-DOT)

Hepatitis C, Chronic

India
Melbourne Health
Hoffmann-La Roche; Monash University; The University of New South Wales; St Vincent... and other collaborators

Completed

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Chronic Hepatitis C

Australia
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
Ruijin Hospital

Unknown

An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

Chronic Hepatitis B
Bristol-Myers Squibb

Withdrawn

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients (COMMAND-Asia)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Hepatitis C, Chronic
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Vertex Pharmaceuticals Incorporated
Tibotec, Inc

Completed

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Netherlands, Austria, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France

3

Subscribe